CClinicalTrials.gg
RecruitingNCT07163416I-GRAINE-NEWUpdated Sep 9, 2025

(Italian Migraine Registry, I-GRAINE-NEW)

An observational study in Migraine Disorders, sponsored by IRCCS San Raffaele Roma. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by IRCCS San Raffaele Roma · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,030
Ages
18 Years and older
Sex
All
01

Study summary

Rationale Understanding the mechanisms and evolution of migraine is hampered by its nature as a chronic "evolutionary" condition. Patients often come to migraine centers after years of disabling disease, non-specific diagnoses and ineffective treatments. When patients are admitted to the center is therefore the time when their history in terms of disease evolution and healthcare costs is most effectively collected, but also when it is assumed that the treatment strategy offered to the patient will have a greater impact.

For this reason, it was decided to conduct a large-scale retrospective and prospective observational study in order to draw a detailed picture of the situation of patients not followed by a specialized center and of the natural history of the disease once the pathway at the specialized center has started.

Design A multicenter, observational, retrospective and prospective cohort study, aimed at obtaining a more detailed picture of the situation of patients not followed by a specialized center and of the natural history of the disease once the pathway at the specialized center has started.6,000 of the incident patients (defined as those who had their first visit during the 6 months preceding enrollment in the registry), will be invited to take part in a follow-up and expanded data collection study.

Patients will be consecutively enrolled by specialists at each individual site.. Eligible patients who agree to take part in the study by signing an informed consent form will be assessed clinically and through a direct interview with a structured questionnaire organized in several ad hoc sections.

Objectives: The aim of the study is:

analyze episodic and chronic migraine in Italy from an epidemiological point of view, especially in terms of prevalence of the two forms of migraine and their endophenotypes in different population subgroups; 2. characterize the demographic distribution and clinical characteristics of patients (including the definition of endophenotypes); 3. measure the influence of the disease on the patient's daily activity, in terms of disability (assessed using the validated MIDAS and HIT-6 scales); 4. study the clinical and care pathway (patient journey) and identify the preferred care pathways based on the characteristics of the patients and the migraine subtype; 5. evaluate the prescribed pharmacological treatments, medical visits and diagnostic procedures performed (ascertaining the degree of adherence to current guidelines); 6. analyze the use of health resources by migraine patients, with particular attention to their impact on the SNS.

Visits and Treatments:

Baseline Visit: Patients enrolled in the study will undergo a thorough clinical and neurological examination.

Follow-up Visits: Clinical data will continue to be collected over time, at each scheduled clinic visit based on the needs of clinical practice.

Study Population: Adult patients of both sexes with episodic or chronic migraine who have recently attended a specialized migraine center in the I-GRAINE-NEW registry.

Estimated Study Duration: The duration of each patient's participation in the study is 24 months from the date of the initial visit to the participating migraine site

02

Conditions studied

  • Migraine Disorders

Browse trials for

Keywords

  • Migraine,Register,Italy
03

In context

Migraine Disorders

1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.

This study's planned enrollment of 2,030 is above the median of 130 across 299 observational studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

IRCCS San Raffaele Roma is the lead sponsor of 63 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The reference population for the registry IGRAINE includes adult patients of both sexes, suffering from episodic or chronic migraine, undergoing treatment at a specialized headache center.

At the time of its launch, 46 headache centers distributed throughout Italy will participate in the registry. To ensure its representativeness, the study sample includes 10% of the total number of patients followed at the centers, selected randomly.

The registry will be enrolled using the "systematic random" method. Participation in the study will be offered to the first patient at the first visit (incident patient) and to the first patient at the follow-up visit (prevalent patient) of each outpatient day at the clinical center.

If the first patient in each category refuses, participation in the study will be offered to the next patient in order of visit in the same category (prevalent or incident). Researchers are advised NOT to skip patients so as not to create a selection bias in the population.

Inclusion criteria

  • Adult Patients(Age ≥ 18 years) of both sexes
  • Diagnosis confirmed of episodic migraine ( \<15 days/month ) with or without aura or chronic migraine (>15days/month) ,with or without headeche due to overuse of analgesics;
  • Provision of signed and dated the Informed Consent Form before the inclusion in the study

Exclusion criteria

Exclusion Criteria:

  • Patients affected by other forms of primary or secondary headaches or in whom the diagnosis is not certain
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,030 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Better definition of the dimensions of the migraine phenomenon in Italian headache centers

    More appropriate estimate of the prevalence of migraines refractory to treatments. In particular: 1.Identification of clinical endophenotypes that can be predictive of evolution and pharmacological . Allodynia will be assessed through the ASC 12 scale. 1. Disability measured using the validated clinical scales MIDAS, HIT-6. 2. Treatments for migraine attacks and preventive therapies

    Time frame: "Baseline visit or (day 1)"" through study completion, an average of 2 year"

  2. Information on the patient's level of awareness and knowledge of the migraine problem

    1\. Information on the times and methods of access to treatments: 1. evaluation of the interval between the onset of the pathology and access to medical care; 2. health tourism (migration of patients to regions other than their own). 5. Critical issues of the current clinical governance and determination of the use of healthcare resources, and in particular: a. Presence or absence of regional PDTA b. Degree of adherence to diagnostic-therapeutic guidelines c. Proper or improper use of diagnostic tests d. Patient traceability e. Definition of the percentage of patients who access visits, tests and treatments through the NHS.

    Time frame: Baseline visit ,through study completion, an average of 2year

07

Study locations

1 of 1 sites recruiting
  • Head, Irccs San Raffaele Roma S.r.l. - Unità per la cura e la ricerca su cefalee e dolore - Dipartimento di Neurologia, Via di Val di Cannuta 250, 00166 Roma (RM) - Italy
    Roma, Roma 00166, Italy
    • Piero NA Barbante, Degree in Medicine and Surgery · Contact · piero.barbanti@sanraffaele.it · +39 0652254027
    • Gabriella Egeo, Degree in Medicine and Surgery · Contact · gabriella.egeo@sanraffaele.it · +39 0652254027
    • Gabriella na Dr. Egeo, Degree in Medicine and Surgery · Sub investigator
    • Cinzia na Dr. Aurilia, Degree in Medicine and Surgery · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07163416
Lead sponsor
IRCCS San Raffaele Roma
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Apr 19, 2021
Primary completion
Dec 15, 2025 (estimated)
Completion
Mar 5, 2026 (estimated)
Last update
Sep 9, 2025

Study contacts

Piero Barbanti, MD
Contact
piero.barbanti@sanraffaele.it
+390652254027

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion